UNICREDIT BANK/CALL/BIOGEN IDEC/400/0.1/17.12.25 | Market Closed - Börse Stuttgart 02:18:55 2024-05-17 pm EDT | ||
| 1.07 EUR | -0.93% |
|
| Current month | +69.84% | ||
| 1 month | +181.58% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
| Date | Price | Change |
|---|---|---|
| 24-05-17 | 1.07 | -0.93% |
| 24-05-16 | 1.08 | -6.90% |
| 24-05-15 | 1.16 | +20.83% |
| 24-05-14 | 0.96 | +3.23% |
| 24-05-13 | 0.93 | +10.71% |
Delayed Quote Börse Stuttgart
Last update May 17, 2024 at 02:18 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BIOGEN INC. |
| Issuer | 
UniCredit
|
| WKN | HD1H9N |
| ISIN | DE000HD1H9N9 |
| Date issued | 2023-12-28 |
| Strike | 400 $ |
| Maturity | 2025-12-17 (579 Days) |
| Parity | 10 : 1 |
| Emission price | 2 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.01 € |
|---|---|
| Lowest since issue | 0.2 € |
| Spread | 0.02 € |
| Spread % | 1.79% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
230.6
USD
Average target price
285.9
USD
Spread / Average Target
+24.01%
- Stock Market
- Warrants
- Warrant
